Harrow, Inc. Total Long-Term Debt
Harrow, Inc. (HROW) had Total Long-Term Debt of $300.00 million as of 2026-03-31, per its 10-Q filed 2026-05-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-05-11
- 2026-03-31: Long-term Debt $300.00M.
- 2025-12-31: Long-term Debt $250.00M.
- 2025-09-30: Long-term Debt $347.24M.
- 2025-06-30: Long-term Debt $250.62M.
| Period end | Long-term Debt |
|---|---|
| 2026-03-31 | $300.00M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $250.00M 10-K · filed 2026-03-02 |
| 2025-09-30 | $347.24M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $250.62M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $256.91M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $262.74M 10-K · filed 2025-03-27 |
| 2024-09-30 | $230.65M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $236.26M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $243.44M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $246.72M 10-K · filed 2024-03-19 |
| 2023-09-30 | $251.98M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $240.25M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $243.89M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $151.77M 10-K · filed 2023-03-23 |
| 2022-09-30 | $98.18M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $99.80M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $101.42M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $103.03M 10-K · filed 2022-03-10 |
| 2021-09-30 | $106.19M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $106.73M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $16.87M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $20.00M 10-K · filed 2021-03-08 |
| 2020-09-30 | $20.84M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $22.04M 10-Q · filed 2020-08-10 |
| 2018-12-31 | $23.46M 10-K · filed 2019-03-12 |
| 2018-03-31 | $23.22M 10-Q · filed 2018-05-15 |
| 2017-12-31 | $23.46M 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |